Werewolf Therapeutics To Present Clinical And Preclinical Data At The Society For Immunotherapy Of Cancer's 38th Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Werewolf Therapeutics (NASDAQ:HOWL) will present interim clinical results from its ongoing Phase 1/1b study of WTX-124 at the Society for Immunotherapy of Cancer's 38th Annual Meeting. The data will provide early insight into the safety and antitumor activity of WTX-124. The company will also present data supporting the potential of its PREDATOR platform and INDUKINE product candidates. A conference call and webcast to review the initial clinical results will be held on November 3, 2023.
October 31, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Werewolf Therapeutics' presentation of interim clinical results from its ongoing Phase 1/1b study of WTX-124 could potentially impact its stock price. Positive results could boost investor confidence, while negative results could have the opposite effect.
The presentation of interim clinical results is a significant event for biopharmaceutical companies. Positive results could boost investor confidence and drive up the stock price, while negative results could lead to a drop in the stock price. However, the exact impact will depend on the details of the results and the market's reaction to them.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100